AIFA announces reimbursement of oral SMA treatment
Insider Insights

Italy: AIFA announces reimbursement of oral SMA treatment


The Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) has announced that Roche’s Evyrsdi (risdiplam) is reimbursed with effect from 8th February 2022 in the national health service (servizio sanitario nazionale, SSN) for 5q spinal muscular atrophy (SMA) in patients from 2 months of age with a clinical diagnosis of SMA type 1, 2 or 3, or who have one to four SMN2 copies.  

According to AIFA, the manufacturer will provide a compulsory discount on the ex-factory price to all health facilities prescribing the drug.  


  1., “Attivazione web e pubblicazione schede di monitoraggio – Register EVRYSDI”, 8th February 2022
  2., “Determina 67/2022 – Evrysdi”, 8th February 2022

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.